13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

36 trials found

diseases per page:

Showing 1 to 10 of 36 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05319093 (ClinicalTrials.gov)	April 2022	1/4/2022	Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients	Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients	Fatigue;Multiple Sclerosis	Drug: Ozanimod	Brigham and Women's Hospital	Bristol-Myers Squibb	Not yet recruiting	18 Years	N/A	All	40		NULL
2	NCT05028634 (ClinicalTrials.gov)	October 27, 2021	25/8/2021	Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multipl ...	A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vac ...	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Biological: Tetanus, diphtheria, and acellular pertussis vaccine;Biological: Pneumococcal polysaccha ...	Celgene	NULL	Recruiting	18 Years	65 Years	All	60	Phase 3	United States;Germany
3	NCT04140305 (ClinicalTrials.gov)	January 16, 2020	24/10/2019	Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated ...	A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Chan ...	Multiple Sclerosis	Drug: RPC-1063	Celgene	NULL	Active, not recruiting	18 Years	65 Years	All	250	Phase 3	United States;Canada;Puerto Rico
4	EUCTR2015-002500-91-SE (EUCTR)	01/06/2017	27/06/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy;South Africa;Latvia;Moldova, Republic ...
5	EUCTR2016-003073-18-GB (EUCTR)	29/09/2016	16/09/2016	A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from ...	A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male ...	The drug is a potential treatment for adult patients with relapsing multiple sclerosis (RMS) and for ...	Product Name: [14C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration INN or Proposed INN: Ozanimo ...	Celgene International II Sàrl	NULL	Not Recruiting			Female: no Male: yes	6	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - ( ...	United Kingdom
6	EUCTR2015-002500-91-HR (EUCTR)	13/06/2016	06/07/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
7	EUCTR2015-002500-91-PT (EUCTR)	06/06/2016	13/04/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis. - Open Lab ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCI Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2496	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
8	EUCTR2015-002500-91-LT (EUCTR)	31/05/2016	17/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
9	EUCTR2015-002500-91-LV (EUCTR)	20/04/2016	19/02/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	2495	Phase 3	United States;Serbia;Belarus;Portugal;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...
10	EUCTR2015-002500-91-EE (EUCTR)	04/04/2016	07/03/2016	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis - Open Labe ...	Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multi ...	Product Name: 0.25mg RPC1063 Product Code: RPC1063 INN or Proposed INN: Ozanimod HCl Product Name: 1.0mg ...	Celgene International II Sàrl (CIS II)	NULL	Not Recruiting			Female: yes Male: yes	2495	Phase 3	United States;Belarus;Portugal;Serbia;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Italy ...

First Previous1 2 3 4Next Last